

# Endocrine Abstracts

September 2020 Volume 70  
ISSN 1479-6848 (online)

22nd European Congress of  
Endocrinology

5-9 September 2020, European Society of Endocrinology

**eECE 2020**  
22nd European Congress of Endocrinology



published by  
**bioscientifica**

Online version available at  
[www.endocrine-abstracts.org](http://www.endocrine-abstracts.org)



## 22<sup>nd</sup> European Congress of Endocrinology 5-9 September 2020, European Society of Endocrinology

### EDITORS

Abstracts were marked by the Abstract Marking Panel and selected by the Programme Organising Committee

### e-ECE 2020 Mini-Programme Organising Committee

Andrea Giustina (Italy), **ESE President**

Martin Reincke (Germany), **ESE President-Elect**

Bulent Yildiz (Turkey), **ESE Treasurer (until May 2020)**

Riccarda Granata (Italy), **ESE Congress Committee Chair**

Attila Balázs Patócs (Hungary), **2020 POC Co-Chair**

Jens Otto Lunde Jørgensen (Denmark), **2020 POC Co-Chair**

Daniela Cota (France), **2021 POC Co-Chair**

Lars Rejnmark (Denmark), **2021 POC Co-Chair**

Ljiljana Marina (Serbia), **EYES Chair**

Manel Puig Domingo (Spain), **2020 POC Member**

Mónica Marazuela (Spain), **ESE Secretary**

### Programme Organising Committee

Riccarda Granata (Italy), **ESE Congress Committee Chair**

Jens Otto Lunde Jørgensen (Denmark), **Clinical Co-Chair**

Attila Balázs Patócs (Hungary), **Basic Science Co-Chair**

Michal Kršek (Czech Republic), **Local Organising Committee Chair**

Zhanna Belaya (Russian Federation)

Nienke Biermasz (The Netherlands)

Jens Bollerslev (Norway)

Daniela Cota (France)

Ashley Grossman (UK)

Csilla Krausz (Italy)

Madalina Musat (Romania)

Uberto Pagotto (Italy)

Agnieszka Piekliko-Witkowska (Poland)

Vincent Prevot (France)

Manel Puig-Domingo (Spain)

Lars Rejnmark (Denmark)

Mark Sherlock (Ireland)

Marilyn Theodoropoulou (Germany)

Pierre Val (France)

AJ van der Lely (The Netherlands)

Wim van Hul (Belgium)

Greisa Vila (Austria)

Maria Chiara Zatelli (Italy)

### Ex Officio Members

Andrea Giustina (Italy), **ESE President**

Martin Reincke (Germany), **ESE President-Elect**

Bulent Yildiz (Turkey), **ESE Treasurer (until May 2020)**

Wiebke Artl (UK), **Editor in Chief, European Journal of Endocrinology**

Josef Köhrle (Germany), **Editor in Chief, Endocrine Connections**

Felix Beuschlein (Switzerland), **ESE Clinical Committee Chair**

Robin Peeters (Switzerland), **ESE Science Committee Chair**

Riccarda Granata (Italy), **ESE Congress Committee Chair**

Marek Ruchala (Poland), **ECAS Representative**

Mehul Dattani (UK) (Switzerland), **ESPE Representative**

Luis Cardoso (Portugal), **EYES Representative**

### Abstract Marking Panel

Marker Name	Country	L Czupryniak	Poland	D Grigorie	Romania	M Krsek	Czech Republic	N Papanas	Greece	E Shestakova	Russia
M Alevizaki	Greece	J Dahlgren	Sweden	P Groop	Finland	A Kurylowicz	Poland	A Patócs	Hungary	M Shestakova	Russia
K Amrein	Austria	P Dahlqvist	Sweden	A Grossman	UK	E Lalli	France	R Peeters	The Netherlands	M Simoni	Italy
C Andoniadou	UK	C Daousi	UK	L Groussin	France	B Langdahl	Denmark	S Pekic	Serbia	J Skrha	Austria
G Assié	France	M Dattani	UK	G Gruden	Italy	B Lapauw	Belgium	N Pellegata	Germany	P Soares	Portugal
S Babajko	France	C Dayan	UK	L Guasti	UK	J Laven	The Netherlands	L Perez-Rivas	Germany	A Solini	Italy
C Badiu	Romania	J de Castro	Portugal	M Haluzik	Czech Republic	G Lavery	UK	H Perrild	Denmark	A Spada	Italy
A Baranowska-Bik	Poland	W de Herder	The Netherlands	R Hampl	Czech Republic	L Laviola	Italy	L Persani	Italy	J Spranger	Germany
A Barlier	France	E de Koning	The Netherlands	V Hána	Czech Republic	L Lazurova	Slovakia	G Perseghin	Italy	A Spyrgioulou	Germany
K Basham	USA	W Dhillon	UK	F Hannan	UK	H Lefebvre	France	M Petakov	Serbia	G Stalla	Germany
A Beckers	Belgium	G Di Dalmazi	Germany	A Heck	Norway	J Leger	France	A Piekliko-Witkowska	Poland	E Stener-Victorin	Sweden
P Beck-Peccoz	Italy	E Diamanti-Kandarakis	Greece	M Heikinheimo	Finland	T Links	The Netherlands	V Pirags	Latvia	C Strasburger	Germany
Z Belaya	Russia	C Dieguez	Spain	A Hoellich	Germany	P Lips	The Netherlands	C Poiana	Romania	C Stratakis	USA
J Bertherat	France	E Dirinck	Belgium	L Holland	The Netherlands	S Llahana	UK	R Poladian	Lebanon	A Tabarin	France
M Bidlingmaier	Germany	M Donath	Switzerland	A Hubalewska-Dydejczyk	Poland	A Luger	Austria	S Polyzos	Greece	T Tankova	Bulgaria
N Biermasz	The Netherlands	J Drouin	Canada	I Huhtaniemi	UK	S Lund	Denmark	P Poplawski	Poland	M Tena-Sempere	Spain
W Bik	Poland	L Duntas	Greece	E Husebye	Norway	R Luque	Spain	V Popović	Serbia	N Tentolouris	Greece
K Birkeland	Norway	A Dwyer	USA	P Igaz	Hungary	D Macut	Serbia	M Porta	Italy	M Terzolo	Italy
K Boelaert	UK	G Eisenhofer	Germany	I Ilvovskaya	Russia	D Maiter	France	M Poutanen	Finland	M Theodoropoulou	Germany
J Boguslawska	Poland	V Elian	Romania	E Isenovic	Serbia	E Mamedova	Russia	D Power	Portugal	C Thompson	Ireland
J Bollerslev	Norway	F Fallo	Italy	M Jaffrain-Rea	Italy	M Mannelli	Italy	M Puig Domingo	Spain	H Timmers	The Netherlands
R Bouillon	Belgium	M Fassnacht	Germany	B Jarzab	Poland	E Mannucci	Italy	C Quarta	France	M Toth	Hungary
M Brandi	Italy	J Favier	France	K Jazdzewski	Poland	F Mantero	Italy	S Radian	Romania	P Touraine	France
D Branisteanu	Romania	R Feelders	The Netherlands	N Jessen	Denmark	G Mantovani	ITALY	O Ragnarsson	Sweden	R Trifanescu	Romania
K Briot	France	U Feldt-Rasmussen	Denmark	D Jezova	Slovakia	M Marazuela	Spain	N Rahman	Finland	A Tsapas	Greece
T Brue	France	F Fernandes Rosa	France	G Johansson	Sweden	L Marina	Serbia	E Rajpert-De Meyts	Denmark	ETsoudis	Germany
G Brunetti	Italy	S Fica	Romania	A Jørgensen	Norway	N Matikainen	Finland	M Rauner	Germany	MTzanela	Greece
C Buchanan	UK	E Fliers	The Netherlands	J Jørgensen	Denmark	C McCabe	UK	G Raverot	France	E Valassi	Spain
P Burman	Sweden	S Franks	UK	U Kaiser	USA	O Meijer	The Netherlands	M Reincke	Germany	G Valk	The Netherlands
H Butz	Hungary	W Fraser	UK	G Kallitsa	Greece	L Metherell	UK	L Rejnmark	Denmark	E van den Akker	The Netherlands
S Cannavo	Italy	J Frystyk	Denmark	C Kanaka-Gantenbein	Greece	D Miljic	Serbia	S Rice	UK	erlands	
J Cap	Czech Republic	L Fugazzola	Italy	G Kanakis	Greece	J Mittag	Germany	M Robledo	Spain	A van der Lely	The Netherlands
C Capatina	Romania	C Fuà	Germany	T Kararup Hansen	Denmark	N Moller	Denmark	P Rodien	France	J van Eck	The Netherlands
M Caprio	Italy	F Gabalec	Czech Republic	D Karasek	Czech Republic	L Morin-Papunen	Finland	H Romijn	The Netherlands	W van Hul	Belgium
P Caron	France	S Gaberšček	Slovenia	N Karavitaki	UK	A Mukherjee	UK	C Ronchi	Italy	M Vantyghem	France
J Castaño	Spain	M Gabete	Spain	A Karlsson	Sweden	M Musat	Romania	R Ross	UK	G Vila	Austria
H Cederberg-		R Gärtner	Germany	S Kaser	Austria	E Nagy	Hungary	R Roussel	France	E Visser	The Netherlands
T Tamminen	Finland	B Gatta Cherifi	France	D Kastelan	Croatia	S Neggers	The Netherlands	N Rucci	Italy	J Visser	The Netherlands
O Chabre	France	L Gennari	Italy	J Kaufman	Belgium	J Newell-Price	UK	M Ruchala	Poland	V Volke	Estonia
P Chanson	France	M Gheorghiu	Romania	M Keil	USA	N Nicolaidis	Greece	E Rutten	Belgium	J Widimsky	Czech Republic
K Chatterjee	UK	I Gherlan	Romania	F Kelestimir	Turkey	D Niculescu	Romania	S Sanack	Turkey	W Wiersinga	The Netherlands
N Cherradi	France	P Giacobini	France	R Kineman	USA	M Niedziela	Poland	D Santi	Greece	I Wilkinson	UK
M Chiara Zatelli	Italy	F Giorgino	Italy	T Kocjan	Slovenia	R Nogueiras	Spain	P Saunders	UK	P Williams	Germany
F Chiarelli	Italy	A Giustina	Italy	J Kopchick	USA	B Obermayer-Pietsch	Austria	C Schalin-Jäänti	Finland	S Wudy	Germany
J Chowen	Spain	M Godlewska	Poland	M Korbonits	UK	C Olareus	Norway	S Schmid	Germany	P Yeoh	UK
S Christin-Maitre	France	J Gomez-Ambrosi	Spain	B Kos-Kudla	Poland	P Oliveira	Portugal	J Schopohl	Germany	B Yildiz	Turkey
M Cohen-Solal	France	D Goulis	Greece	C Krausz	Italy	D Olsson	Sweden	D Schulte	Germany	M Zarkovic	Serbia
D Cota	France	R Granata	Italy	M Kroiss	Germany	K Øystese	Norway	P Schwarz	Denmark	M Zennaro	France
D Cuthbertson	UK	C Gravholt	Denmark	N Krone	UK	U Pagotto	Italy	M Sherlock	Ireland		

**AEP397****Exposure to phenolic compounds (Bisphenol A and Methyl Paraben) in pregnancy and its relationship with gestational diabetes mellitus, insulin homeostasis and pancreatic beta cell function**

Joaquín Serrano<sup>1</sup>, Antonio Picó-Alfonso<sup>1</sup>, Mariana F Fernández<sup>2</sup>, Juan Pedro Arrebola<sup>3</sup>, Rocío Alfayate-Guerra<sup>4</sup>, María Teresa López<sup>5</sup> & Oscar Moreno-Perez<sup>1</sup>

<sup>1</sup>Endocrinology and Nutrition Department, Hospital General Universitario de Alicante – ISABIAL, Miguel Hernandez University., Alicante, Spain; <sup>2</sup>Universidad de Granada, Centro de Investigación Biomédica, Instituto de Investigación Biosanitaria (ibs. GRANADA), Granada, Spain; <sup>3</sup>CIBER de Epidemiología y Salud Pública (CIBERESP), Granada, Spain; <sup>4</sup>Laboratorio de Hormonas, Hospital General Universitario de Alicante. ISABIAL., Alicante, Spain; <sup>5</sup>Laboratorio de Hormonas, Hospital Universitario de San Juan. FISABIO., San Juan de Alicante, Spain

**Objectives**

The effect of exposure to endocrine disruptors (exogenous chemical compounds that interfere with hormonal homeostasis), such as Bisphenol A (BPA) and Methyl Paraben (MPB), on gestational diabetes mellitus (GDM) has only been investigated in a small number of studies, with inconclusive results. Our objective was to investigate the association between concentrations of BPA and MPB in urine and the presence of DMG, insulin sensitivity and function of beta cells in a cohort of pregnant women in the Mediterranean area.

**Material and methods**

Multicenter case-control study, nested in a gestational cohort. Sequential sampling of women with pathological O'Sullivan (week 24–27 gestation), and indication of GDM confirmation test (OGTT 100 g, 3 h) was performed. We analyzed the presence of GDM (Carpenter and Coustan), insulin sensitivity through Matsuda-SOG Index (WBSII), and beta cell function by a trapezoidal model with calculation of the incremental area of insulin and glucose under the curve (AUCins and AUGglu, respectively), and by disposition index (DI) [(AUCins / AUGglu) \* WBSII]. Concomitantly, urine concentrations of BPA and MPB were quantified by liquid chromatography coupled to mass spectrometry (HPLC-MS). The relationship between the urinary levels of BPA and MPB with the dependent variables was studied using Spearman correlation tests and multivariate logistic and linear regression models.

**Results**

Of the 110 women included 34.5 [29–38] years old, 26 [24.7–28] weeks of gestation, BMI 27.9 [24–32] kg/m<sup>2</sup>, 40.4% of them met the GDM criteria. The study population had a urinary concentrations of BPA 2.95 [1.17–4] µg/l, and MPB 12.1 [4.4–35.4] µg/l. BPA levels of the 3rd vs 1st tertile were not associated with an increased risk of GDM [OR 0.84 (0.3–2.3)], neither with differences in WBSII or DI. These variables were also not correlated by Spearman. 3rd vs MPB levels 1st tertile were not associated with an increased risk of GDM [0.76 (0.3–1.9)], but with a higher WBSII (*P*<0.01). A negative correlation was also found between MPB and HbA1c, HOMA-IR, AUCins / AUGglu and positive with WBSII (*P*<0.05). This relationship disappears when a multivariate linear regression analysis is performed, in which it is found that BMI (B=-0.1, *P*=0.002) would be the only independent factor associated with WBSII.

**Conclusions**

In pregnant women with pathological O'Sullivan, higher concentrations of BPA or MPB in urine were not associated with an increased risk of GDM, lower insulin sensitivity, or lower beta cell function.

DOI: 10.1530/endoabs.70.AEP397

**AEP398****The prophylactic effects of metoprolol, diltiazem and pilocarpine on hypoglycemia-induced prolongation of QT interval**

Eylem Cagiltay<sup>1</sup> & Sjaak Pouwels<sup>2</sup>

<sup>1</sup>Istanbul Bilim Üniversitesi Tıp Fakültesi, Turkey; <sup>2</sup>Street Elisabeth Hospital, Tilburg, Netherlands

**Background**

Insulin-induced hypoglycemia has been demonstrated to prolong the corrected QT (QTc) interval. Prolongation of QTc interval, especially in diabetic patients using insulin, can cause fatal ventricular arrhythmias. The aim of this study was to evaluate the effects of metoprolol, diltiazem and pilocarpine on hypoglycemia-induced QTc prolongation.

**Methods**

Thirty rats were randomly distributed into the following five groups: Group 1 (1 ml/kg saline, *n*=6), Group 2 (40 U/kg crystalline insulin+saline, *n*=6), Group 3 (40 U/kg crystalline insulin+1 mg/kg metoprolol, *n*=6), Group 4 (40 U/kg crystalline insulin+0.8 mg/kg pilocarpine, *n*=6), Group 5 (40 U/kg crystalline insulin+2 mg/kg diltiazem, *n*=6). Three hours after insulin injection, blood glucose level was measured in all groups. Blood glucose <40 mg/dl was defined as hypoglycemia. Electrocardiograms (ECG) were taken in lead I (DI) and QTc was calculated by using Bazett's formula.

**Results**

Group 2 (insulin+saline) showed that they had significantly prolonged QTc interval compared to control group (*P*<0.0001). However, treatments of the rats with metoprolol, pilocarpine and diltiazem significantly prevented the prolongation of QTc interval compared to insulin+saline group (*P*<0.005, *P*<0.005 and *P*<0.01, respectively).

**Conclusion**

The findings of the present study demonstrated the efficacy of metoprolol, pilocarpine and diltiazem in the prevention of hypoglycemia-induced QTc prolongation. These agents may be considered in the prophylactic therapy of high-risk patients who are using insulin.

DOI: 10.1530/endoabs.70.AEP398

**AEP399****Serum vaspin level in patients with diabetes mellitus type 2 as a predictive index of atherosclerosis**

Daniel Pylov<sup>1</sup>, Ivan Smirnov<sup>2</sup> & Larysa Zhuravlyova<sup>1</sup>

<sup>1</sup>Kharkiv National Medical University, Internal Medicine #3 and Endocrinology, Kharkiv, Ukraine; <sup>2</sup>Kharkiv Regional Hospital, Head of Endocrinology Department, Kharkiv, Ukraine

**Background**

It has been proved that the adipose tissue is an active endocrine organ. It secretes a large number of adipokines which are involved in and affect regulation of metabolic process and can influence pathogenesis of atherosclerosis. Vaspin-new representative of adipokines which is secreted by adipose tissue and have an insulin-sensitizing properties. Vaspin engagement into atherosclerotic process poorly investigated.

**Aim**

To establish the value of plasma vaspin level in patients with diabetes mellitus type 2 (DM2) for prediction cardiovascular disease.

**Methods**

Thirty-one patient (55.1±1.9 years) with DM2 (9.1±2.8 years of duration) who do not have major adverse cardiovascular events were included to the study. The BMI (28.18±0.8 kg/m<sup>2</sup>), fasting plasma glucose level (FPG), HbA<sub>1c</sub>, total cholesterol (TC), low-density lipoproteins (LDL), triglycerides (TG), C reactive protein (CRP) serum vaspin level and intima media thickness of carotid arteries (IMT CA) by ultrasound were measured. Control group healthy volunteers (54.8±1.1 years) matched for age, gender and BMI.

**Results**

The study results showed that all patients had an adequate control of DM2 by oral hypoglycemic agents FPG 8.18±0.92 mmol/l; HbA<sub>1c</sub> 7.49±0.21%. Dyslipidemia was present TC 6.40±0.63 mmol/l; LDL 3.39±0.52 mmol/l, TG 2.35±0.15 mmol/l and there is no active process of inflammation CRP 1.33±0.12. Serum vaspin level was significantly higher in patients with DM2 than in control group 3.47±0.42 pg/ml vs 2.42±0.19 pg/ml, *P*<0.05). In multivariate analysis after adjusting for atherosclerotic risk factors vaspin had positive correlation with IMT CA 1.02±0.23 mm vs 0.71±0.11 mm (*r*=0.37, *P*<0.02); immunoreactive insulin (0.6 *P*<0.001) FPG (0.62 *P*<0.001), HbA<sub>1c</sub> (0.56, *P*<0.001), TG (*r*=0.31, *P*<0.04). No significant correlation was found between vaspin and BMI, TC, LDL, and plaque existence in carotid arteries.

**Conclusions**

Serum vaspin level was found significantly higher in patients with DM2 and thicker intima media than age-matched healthy subjects with normal IMT. The vaspin level had significant correlation with all known parameters which are involved in and promoted atherogenesis. Therefore, vaspin may have a pleiotropic effects and can be engaged in atherosclerosis development.

DOI: 10.1530/endoabs.70.AEP399